Clinical trials: Relapsed Lymphoblastic Leukemia
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
This study is testing a new type of treatment called anti-CD19 CAR-T cell therapy for adults with certain blood cancers that have returned or did not respond to previous treatments.
- Trial name
- NCT06705530
- Testing
- Hem101
- Where
- Russia
- Volunteers
- 58 people
- Sponsor
- National Research Center for Hematology, Russia
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06191887
- Testing
- Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
This is a Phase 1b and 2, open-label, single-arm study evaluating the safety, tolerability, and efficacy of roginolisib (IOA-244) in combination with obinutuzumab followed by venetoclax in patients with relapsed or refractory…
- Trial name
- NCT07847957
- Testing
- Roginolisib, Obinutuzumab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
This phase I trial studies the side effects and the best dose of alisertib when given together with vorinostat in treating patients with Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma that has come…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT01567709
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT).
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
- Trial name
- NCT03751709
- Testing
- Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cedars-Sinai Medical Center
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma
Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma
To evaluate the efficacy and safety of anti-CD1a CAR-T in the treatment of relapsed refractory acute T-lymphoblastic leukemia/lymphoblastic lymphoma.
- Trial name
- NCT05745181
- Testing
- CAR-T Cell Infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphocytic, Chronic, B-Cell
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment…
- Trial name
- NCT02759016
- Testing
- BI 836826, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.
- Conditions
- B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
- Trial name
- NCT03056339
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Relapsed Chronic Lymphocytic Leukemia
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism…
- Trial name
- NCT01750567
- Testing
- Metformin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Lymphoid Leukemia
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of debulking with bendamustine followed by induction and maintenance with GA101 (obinutuzumab)…
- Trial name
- CLL2-BAAG (NCT03787264)
- Testing
- Bendamustine, Obinutuzumab, Acalabrutinib
- Where
- 17 sites in Germany
- Volunteers
- 46 people
- Sponsor
- German CLL Study Group
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkins Lymphoma, Hodgkin's Disease
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
The purpose of this study is to estimate the maximum tolerated dose of dexamethasone given for 5 consecutive days when combined with fixed doses of irinotecan (given IV, qd x 5, 2 days off, qd x 5) and vincristine (given IV, 2…
- Conditions
- Non-Hodgkins Lymphoma, Hodgkin's Disease, Acute Lymphoblastic Leukemia
- Trial name
- NCT00718757
- Testing
- Dexamethasone, Irinotecan, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
- Trial name
- NCT04930536
- Testing
- Acalabrutinib capsule
- Where
- 15 sites in India
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Trial name
- NCT02717611
- Testing
- ACP-196 (acalabrutinib)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Acerta Pharma BV